Eating antiviral drugs can occur blindness at herpes patients

Researchers from the universities of Pennsylvania and New York have discovered that taking an antiviral agent can help prevent the facial damage associated with the ‘sheep of the herpes’ that affects the eye. Distributed herpes -virus disease affects sensory nerves and can lead to a painful rash. In some cases, herpes can affect the eye, leading to inflammation of the corneal, iris -inflammation or inflammation of other parts of the eye. If the herpes is not treated appropriately, it can lead to vision damage. In some cases, it can lead to legal blindness, that is, a great loss of vision. The study published at the activities of the American Academy of Eye Medicine in the US state of Illinois during the activities of the Illinois’ annual meeting is the first of its kind to show that taking an antiviral agent for a year can help prevent the visibility associated with the area. The researchers have indicated that this discovery can change the method of treating this disease. The in -child herpes starts in the nerve that connects the brain to the eye, almost a million people in the United States every year. About 30,000 cases of herpes in a type of herpes are reduced to the vision of patients up to 20/60 or worse, and that means that if someone is visible to see something clearly 20 meters away, these patients must move at least 7 meters to see him. In addition, about 10,000 patients suffer from blind herpes, which means a decrease in their eyesight to 20/200 or worse. The reduction of the risk for patients suffering from the regular infection of the In -kind of herpes. There was no clear therapeutic path to prevent complications such as visual loss. Dr. Elizabeth Cohen, a professor of ophthalmology at the Grossman College of Medicine at the University of New York, designed the study after her herself was influenced by the loss of vision related to herpes -long periods. The study examined the long -term use of antiviral therapy “valcicofer”, which is already used to initially treat any conditions of herpes, although only 7 to 10 days. The researchers have shown that the use of ValcicOffir for a year can reduce the risk of new or worse eye diseases by 26% after 18 months after the start of treatment. Patients treated with vasiklofir were also 30% less than those who did not receive treatment for multiple attacks from herpes after a year or a year and a half. The researchers hope that their work will create a relatively simple path to prevent changes in the vision that can change life, as this drug has already become part of the regular clinical treatment of herpes, so that the researchers do not suggest that major barriers prevent a standard for treatment.